Cereno Scientific reports positive Phase I PK-bridging results for CS014, backs direct move to Phase IIb in PH-ILD

By Public Technologies
  • Cereno Scientific reported positive topline results from a Phase I pharmacokinetic bridging study of HDAC inhibitor CS014.
  • Results have been presented as topline data; fuller findings are slated for publication in 2027.
  • Study supported the planned regulatory strategy to move CS014 directly into Phase IIb in PH-ILD, pending FDA review.
  • Safety profile was consistent with prior Phase I experience, with mild adverse events and no serious events.
  • IND submission is planned for Q4 2026; Phase IIb start is targeted for Q3 2027, subject to regulatory clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.